Direct-to-consumer genetic testing has been receiving a lot of attention over the past 10 years from medical providers, consumers, consumer advisory boards, regulatory entities, and ethicists.
Whole-genome sequencing of healthy people reveals that while some are at risk for rare genetic diseases, the implications remain unknown.
The FDA has approved the first home genetic tests for 10 diseases or conditions.
Clinical Pain Advisor Articles
- Opioid Use in Chronic Low Back Pain: A Population Study
- Risks Associated With Co-Administration of Aspirin and Other NSAIDs
- FDA Approves Aimovig for Migraine Prevention
- Stages of Low Back Pain Have Specific Sets of Clinical Indicators
- First Non-Opioid Drug Approved for Managing Opioid Withdrawal Symptoms
- Effect of Prescription Drug Monitoring Programs on Fatal, Nonfatal Drug Overdoses
- Standardized SCS Workflow May Effectively Alleviate Failed Back Surgery Syndrome-Related Pain
- Marijuana Legalization and Opioid Prescribing Rates
- Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes
- Interbrain Coupling During Handholding Associated With Analgesia, Empathy
- Opioid-Related Adverse Drug Events Associated With Worse Patient, Cost Outcomes
- Education Plus Exercise, Single Corticosteroid Injection Effective in Long Term for Gluteal Tendinopathy
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Naloxone Training Beneficial for PA Students
- Supervised Injection Sites Hailed as the Latest Strategy to Fight the Opioid Crisis